Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

ABSTRACT:

Background

Stage IV colorectal cancer encompasses a broad patient population in which both curative and palliative management strategies may be used. In a phase II study primarily designed to assess the efficacy of capecitabine and oxaliplatin, we were able to prospectively examine the outcomes of patients with stage IV colorectal cancer according to the baseline resectability status.

Methods

At enrolment, patients were stratified into three subgroups according to the resectability of liver disease and treatment intent: palliative chemotherapy (subgroup A), conversion therapy (subgroup B) or neoadjuvant therapy (subgroup C). All patients received chemotherapy with capecitabine 2000 mg m(-2) on days 1-14 and oxaliplatin 130 mg m(-2) on day 1 repeated every 3 weeks. Imaging wa

SUBMITTER: Watkins DJ 

PROVIDER: S-EPMC2816665 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature